Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Comparison of the Clinical Outcomes of Nilotinib and Dasatinib Therapies in Newly Diagnosed Patients in the Chronic Phase of Chronic Myeloid Leukemia: A Retrospective Analysis

Noriyoshi Iriyama, MD PhD, Kei-Ji Sugimoto, Eriko Sato, MD PhD, Tomoiku Takaku, MD PhD, Michihide Tokuhira, Tomonori Nakazato, MD PhD, Maho Ishikawa, MD, Hiroyuki Fujita, MD PhD, Yuta Kimura, MD, Isao Fujioka, MD, Norio Asou, MD PhD, Masahiro Kizaki, MD PhD, Norio Komatsu, MD PhD, Yoshihiro Hatta, MD PhD, Tatsuya Kawaguchi, MD PhD

Blood (2018) 132 (Supplement 1): 4268.

https://doi.org/10.1182/blood-2018-99-111732

Published: 2018

Journal Articles

Dual Targeting of Cell-Cycle Checkpoint Kinase and Unfolded Protein Response As a Novel Therapeutic Approach for High-Risk Multiple Myeloma with TP53 Deletion or Mutations

Yuka Tanaka, MD, Takayuki Tabayashi, MD PhD, Yasuyuki Takahashi, MD PhD, Yuta Kimura, MD, Tatsuki Tomikawa, MD PhD, Junichi Watanabe, MD PhD, Tomoe Anan-Nemoto, MD PhD, Morihiko Sagawa, MD PhD, Reiko Watanabe, MD PhD, Michihide Tokuhira, Masahiro Kizaki, MD PhD

Blood (2018) 132 (Supplement 1): 5613.

https://doi.org/10.1182/blood-2018-99-116247

Published: 2018

Journal Articles

Inhibition of WEE1 Induces Cell Death of Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma Cells: A Novel Therapeutic Approach Targeting Cell-Cycle Checkpoint Kinase

Takayuki Tabayashi, MD PhD, Yuka Tanaka, MD, Yasuyuki Takahashi, MD, Yuta Kimura, MD, Tatsuki Tomikawa, MD, Morihiko Sagawa, MD PhD, Tomoe Anan-Nemoto, MDPhD, Reiko Watanabe, MD PhD, Michihide Tokuhira, MD PhD, Masahiro Kizaki, MD PhD

Blood (2016) 128 (22): 3256.

https://doi.org/10.1182/blood.V128.22.3256.3256

Published: 2016

Journal Articles

The Efficacy and Safety of Weekly Bortezomib Containing VMP Followed By Bortezomib Maintenance Therapy in Unfit or Frail Multiple Myeloma Patients

Naoki Takezako, MD PhD, Michihide Tokuhira, MD PhD, Naohiro Sekiguchi, MD PhD, Yuya Kurihara, MD, Kenichi Ito, MD, Miwa Kurimoto, MD PhD, Kenshi Suzuki, MD PhD, Masahiro Kizaki, MD PhD

Blood (2016) 128 (22): 4529.

https://doi.org/10.1182/blood.V128.22.4529.4529

Published: 2016

Journal Articles

CD14-CD15+, Possible Cells Are Potent Myeloid-Derived Suppressor Cells, Which Affect the Pathogenesis of Induction and Regression in Methotrexate-Mediated Lymphoproliferative Disorders

Michihide Tokuhira, MD PhD, Shuntaro Saito, MD, Yuka Tanaka, MD, Yasuyuki Takahashi, MD, Yuta Kimura, MD, Tatsuki Tomikawa, MD, Tomoe Anan, MD, PhD, Shuji Momose, MD PhD, Morihiro Higashi, MD, PhD, Takayuki Shimizu, MD PhD, Takehiko Mori, MD PhD, Takayuki Tabayashi, MD PhD, Reiko Watanabe, MD PhD, Jun-ichi Tamaru, MD, PhD, Shinichiro Okamoto, MD PhD, Masahiro Kizaki, MD PhD

Blood (2016) 128 (22): 2946.

https://doi.org/10.1182/blood.V128.22.2946.2946

Published: 2016

Journal Articles

Preliminary Results from a Phase 1/2 Study of DSP-7888, a Novel WT1 Peptide-Based Vaccine, in Patients with Myelodysplastic Syndrome (MDS)

Shigesaburo Miyakoshi, MD PhD, Kensuke Usuki, MD PhD, Itaru Matsumura, MD PhD, Yasunori Ueda, MD PhD, Hiromi Iwasaki, MD PhD, Toshihiro Miyamoto, MD PhD, Makoto Origuchi, Shuzo Tagashira, Ichiro Naoi, Tomoki Naoe, MD PhD, Masahiro Kizaki, MD PhD, Yuji Heike, MD PhD, Koichi Akashi, MD PhD, Yasushi Miyazaki, MD PhD

Blood (2016) 128 (22): 4335.

https://doi.org/10.1182/blood.V128.22.4335.4335

Published: 2016

Journal Articles

A Phase 1/2 Study of WT1 Peptide Cancer Vaccine WT4869 in Patients with Myelodysplastic Syndromes (MDS)

Takahiro Suzuki, MD PhD, Yasunori Ueda, MD PhD, Michinori Ogura, MD PhD, Toshiki Uchida, MD PhD, Keiya Ozawa, MD PhD, Shigesaburo Miyakoshi, MDPhD, Tomoki Naoe, MD PhD, Makoto Murata, MD PhD, Masahiro Kizaki, MD PhD, Naokuni Uike, MD, Yasunobu Abe, MD PhD, Michihiro Hidaka, MD PhD, Shuzo Tagashira, Satoru Tsuchiya, Kazuma Ohyashiki, MD PhD, Yasushi Miyazaki, MD PhD

Blood (2015) 126 (23): 2868.

https://doi.org/10.1182/blood.V126.23.2868.2868

Published: 2015

Journal Articles

Novel Therapeutic Approach to Overcome Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma By Targeting TOPK/PBK

Takayuki Tabayashi, MD PhD, Yasuyuki Takahashi, MD, Yuta Kimura, MD, Tatsuki Tomikawa, MD, Tomoe Nemoto-Anan, MD PhD, Reiko Watanabe, MD PhD, Michihide Tokuhira, MD PhD, Masahiro Kizaki, MD PhD

Blood (2015) 126 (23): 1763.

https://doi.org/10.1182/blood.V126.23.1763.1763

Published: 2015

Journal Articles

Successful Management of Transplant-Ineligible Patients with Refractory/Relapsed Multiple Myeloma By Using a Biweekly or Longer Modified Bortezomib Schedule As Interval Maintenance therapy

Michihide Tokuhira, MD PhD, Yuta Kimura, MD, Tatsuki Tomikawa, Yasuyuki Takahashi, Morihiko Sagawa, MD PhD, Tomoe Nemoto, MD, Takayuki Tabayashi, MD PhD, Reiko Watanabe, MD PhD, Masahiro Kizaki, MD PhD

Blood (2014) 124 (21): 5758.

https://doi.org/10.1182/blood.V124.21.5758.5758

Published: 2014

Journal Articles

TM-233 Exerts Anti-Myeloma Activity and Overcomes Bortezomib-Resistance In Human Multiple Myeloma Cells By Targeting NF-κB and JAK/STAT Dual-Signaling Pathways

Morihiko Sagawa, MD, PhD, Tatsuki Tomikawa, MD, Tomoe Anan, MD, Takayuki Tabayashi, MD, PhD, Reiko Watanabe, MD, PhD, Michihide Tokuhira, MD, PhD, Masaki Ri, MD, PhD, Yuichi Hashimoto, PhD, Shinsuke Iida, MD, PhD, Masahiro Kizaki, MD, PhD

Blood (2013) 122 (21): 4427.

https://doi.org/10.1182/blood.V122.21.4427.4427

Published: 2013

Journal Articles

Discovery of Unique Biomarkers That Predict Bortezomib-Induced Peripheral Neuropathy: The Results of a Multicenter Prospective Clinical Study of Multiple Myeloma in Japan

Takashi Watanabe, MD, PhD, Masato Mitsuhashi, MD, PhD, Morihiko Sagawa, MD, PhD, Kenshi Suzuki, MD, PhD, Masaki Ri, MD, PhD, Masahiro Abe, MD, PhD, Ken Ohmachi, MD, Yasunori Nakagawa, MD, PhD, Shingen Nakamura, MD, Mizuki Chosa, PhD, Shinsuke Iida, MD, PhD, Masahiro Kizaki, MD, PhD

Blood (2012) 120 (21): 1816.

https://doi.org/10.1182/blood.V120.21.1816.1816

Published: 2012

Journal Articles

A Biomarker Obtained From Whole Peripheral Blood Predicts Response to Bortezomib: Results of a Multicenter Prospective Clinical Study of Multiple Myeloma in Japan.

Blood (2012) 120 (21): 2954.

https://doi.org/10.1182/blood.V120.21.2954.2954

Published: 2012

Journal Articles

TM-233, a Novel Analog of 1'-Acetoxychavicol Acetate (ACA), Induces Cell Death in Human Myeloma Cells by Inhibiting Both JAK/STAT and NF-κB Pathways: A Possible New Agent for Overcoming Bortezomib-Resistance.

Morihiko Sagawa, MD, PhD, Tatsuki Tomikawa, MD, Tomoe Nemoto, MD, Takayuki Tabayashi, MD, PhD, Reiko Watanabe, MD, PhD, Michihide Tokuhira, MD, PhD, Masaki Ri, MD, PhD, Yuichi Hashimoto, PhD, Shinsuke Iida, MD, PhD, Masahiro Kizaki, MD, PhD

Blood (2012) 120 (21): 2939.

https://doi.org/10.1182/blood.V120.21.2939.2939

Published: 2012

Journal Articles

Gold Compound Auranofin (RIDAURA®) Induces Apoptosis of Human Myeloma Cells by Targeting STAT3 and NF-κB Pathways, with Clinical Potential.

Morihiko Sagawa, MD, Aya Nakaya, MD, Tatsuki Tomikawa, MD, Yuichiro Haba, MD, Tomoe Nemoto, MD, Kyoko Hanzawa, MD, Reiko Watanabe, MD, Michihide Tokuhira, MD, Shigehisa Mori, MD, Hideo Uchida, MD, Akihiro Muto, MD, PhD, Masahiro Kizaki, MD, PhD

Blood (2009) 114 (22): 3837.

https://doi.org/10.1182/blood.V114.22.3837.3837

Published: 2009

NARROW

Comparison of the Clinical Outcomes of Nilotinib and Dasatinib Therapies in Newly Diagnosed Patients in the Chronic Phase of Chronic Myeloid Leukemia: A Retrospective Analysis

Dual Targeting of Cell-Cycle Checkpoint Kinase and Unfolded Protein Response As a Novel Therapeutic Approach for High-Risk Multiple Myeloma with TP53 Deletion or Mutations

Inhibition of WEE1 Induces Cell Death of Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma Cells: A Novel Therapeutic Approach Targeting Cell-Cycle Checkpoint Kinase

The Efficacy and Safety of Weekly Bortezomib Containing VMP Followed By Bortezomib Maintenance Therapy in Unfit or Frail Multiple Myeloma Patients

CD14-CD15+, Possible Cells Are Potent Myeloid-Derived Suppressor Cells, Which Affect the Pathogenesis of Induction and Regression in Methotrexate-Mediated Lymphoproliferative Disorders

Preliminary Results from a Phase 1/2 Study of DSP-7888, a Novel WT1 Peptide-Based Vaccine, in Patients with Myelodysplastic Syndrome (MDS)

A Phase 1/2 Study of WT1 Peptide Cancer Vaccine WT4869 in Patients with Myelodysplastic Syndromes (MDS)

Novel Therapeutic Approach to Overcome Both Bortezomib- and Lenalidomide-Resistant Multiple Myeloma By Targeting TOPK/PBK

Successful Management of Transplant-Ineligible Patients with Refractory/Relapsed Multiple Myeloma By Using a Biweekly or Longer Modified Bortezomib Schedule As Interval Maintenance therapy

TM-233 Exerts Anti-Myeloma Activity and Overcomes Bortezomib-Resistance In Human Multiple Myeloma Cells By Targeting NF-κB and JAK/STAT Dual-Signaling Pathways

Discovery of Unique Biomarkers That Predict Bortezomib-Induced Peripheral Neuropathy: The Results of a Multicenter Prospective Clinical Study of Multiple Myeloma in Japan

A Biomarker Obtained From Whole Peripheral Blood Predicts Response to Bortezomib: Results of a Multicenter Prospective Clinical Study of Multiple Myeloma in Japan.

TM-233, a Novel Analog of 1'-Acetoxychavicol Acetate (ACA), Induces Cell Death in Human Myeloma Cells by Inhibiting Both JAK/STAT and NF-κB Pathways: A Possible New Agent for Overcoming Bortezomib-Resistance.

Gold Compound Auranofin (RIDAURA®) Induces Apoptosis of Human Myeloma Cells by Targeting STAT3 and NF-κB Pathways, with Clinical Potential.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only